Terug
43
Dagbereik
€ 367,87
€ 367,90
52-Weeksbereik
€ 362,28
€ 535,75
Volume
1
50D / 200D Gem.
€ 383,12
/
€ 435,98
Vorige Slotkoers
€ 367,90
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 57,4 | 0,4 |
| P/B | 7,4 | 2,9 |
| ROE % | 13,5 | 3,8 |
| Net Margin % | 11,7 | 3,9 |
| Rev Growth 5Y % | 16,7 | 10,0 |
| D/E | 0,4 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 18,21
€ 16,86 – € 18,81
|
1 B | 1 |
| FY2029 |
€ 18,37
€ 17,01 – € 18,97
|
930 M | 1 |
| FY2028 |
€ 15,60
€ 14,44 – € 16,11
|
800 M | 1 |
Belangrijkste Punten
Revenue grew 16,71% annually over 5 years — strong growth
ROE of 13,49% — decent returns on equity
Debt/Equity of 0,39 — conservative balance sheet
Negative free cash flow of -128,95M
P/E of 57,37 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 19,83%
Groei
Revenue Growth (5Y)
16,71%
Revenue (1Y)36,54%
Earnings (1Y)11,66%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
13,49%
ROIC8,94%
Net Margin11,68%
Op. Margin15,07%
Veiligheid
Debt / Equity
0,39
Current Ratio0,86
Interest Coverage16,99
Waardering
P/E Ratio
57,37
P/B Ratio7,39
EV/EBITDA46,53
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 36,54% | Revenue Growth (3Y) | 22,69% |
| Earnings Growth (1Y) | 11,66% | Earnings Growth (3Y) | 30,64% |
| Revenue Growth (5Y) | 16,71% | Earnings Growth (5Y) | 96,99% |
| Profitability | |||
| Revenue (TTM) | 748,87M | Net Income (TTM) | 87,50M |
| ROE | 13,49% | ROA | 6,58% |
| Gross Margin | 39,00% | Operating Margin | 15,07% |
| Net Margin | 11,68% | Free Cash Flow (TTM) | -128,95M |
| ROIC | 8,94% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,39 | Current Ratio | 0,86 |
| Interest Coverage | 16,99 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 57,37 | P/B Ratio | 7,39 |
| P/S Ratio | 6,70 | PEG Ratio | 4,28 |
| EV/EBITDA | 46,53 | Dividend Yield | 0,01% |
| Market Cap | 5,02B | Enterprise Value | 5,25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 748,87M | 548,46M | 497,46M | 464,84M | 403,66M |
| Net Income | 87,50M | 78,37M | 51,28M | 23,11M | 5,81M |
| EPS (Diluted) | 6,41 | 5,74 | 3,82 | 1,82 | 0,46 |
| Gross Profit | 292,07M | 189,05M | 140,59M | 113,82M | 94,83M |
| Operating Income | 112,85M | 86,22M | 37,30M | 24,40M | 769.000,0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,33B | 1,10B | 861,88M | 756,91M | 717,68M |
| Total Liabilities | 650,66M | 483,66M | 291,57M | 356,63M | 313,54M |
| Shareholders' Equity | 679,69M | 617,73M | 562,33M | 392,54M | 395,39M |
| Total Debt | 267,00M | 256,00M | 157,00M | 267,00M | 215,00M |
| Cash & Equivalents | 36,50M | 74,02M | 24,48M | 15,86M | 18,15M |
| Current Assets | 426,95M | 337,95M | 208,33M | 193,58M | 185,14M |
| Current Liabilities | 496,19M | 440,22M | 258,99M | 237,34M | 272,38M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Capital Heavy Grower
#60 of 75
Recente Activiteit
Ingestapt
Capital Heavy Grower
Mar 24, 2026